UbiQ Therapeutics


UbiQ Therapeutics, a business division of UbiQ Bio, was established in 2015 with the aim to expand UbiQ’s drug discovery efforts by teaming up with pharma partners


mission

Discovering the therapeutic value of the ubiquitin system.

 

focus

  • Developing ubiquitylation inhibitors based on our Triple E platform.
  • Creating value in our first Triple E program: R107, a targeted therapy for Myc-driven cancers.
  • Building a pipeline based on our Triple E platform and entering into strategic alliances.

 

proprietary position

A patent application on the Triple E Platform technology has been filed in 2014, one in the EU and a provisional application in the US. 


contact

For more information please contact Boris Rodenko, our VP Translational Drug Discovery borisrodenko[at]UbiQbio.com

 

development pipeline 

project target indication drug discovery  pre-clinical clinical
UbiQ-R103  undisclosed DUB breast cancer

 

pijl 1

   
UbiQ-R105 CNS 

 CNS

 

pijl2 

 

 
UbiQ-R107

SUMOylation cascade

cancer 

 

pijl4